Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN + Benda)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Columbia University
Sponsor:
Collaborators:
British Columbia Cancer Agency
Princess Margaret Hospital, Canada
Information provided by (Responsible Party):
Owen A. O'Connor, Columbia University
ClinicalTrials.gov Identifier:
NCT01657331
First received: August 2, 2012
Last updated: April 9, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2015
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)